Search
OpenAI is introducing an early-stage artificial intelligence model, GPT-Rosalind, designed to accelerate drug discovery. Targeted at life sciences research, this model can extract insights from vast amounts of data, helping to translate scientific research into patient-oriented medical applications. OpenAI stated that the model will initially be made available to select enterprise customers as a research preview, with the first batch of users including pharmaceutical company Amgen, vaccine manufacturer Moderna, and the non-profit Allen Institute for Biological Science. Currently, OpenAI, Anthropic, and Alphabet's Google are increasingly focusing on the application of AI in scientific and medical fields, such as aiding in the development of new drugs and analyzing personal medical data.
-
C114 Communication Network -
Communication Home
